VIDEO: Approval of Voranigo ‘big victory’ in treatment of young patients with brain tumors

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Recently we had the FDA approvals. In August of 2024, we had the FDA approval of vorasidenib, or the commercial name is Voranigo, I think that's how we pronounce it. But vorasidenib, which is for patients with grade 2 IDH-mutated tumor. And what is nice is the approval is for patients 12 and older. So, it's really also, right, the children, or teenager and older. So, 12 and older that are grade 2 IDH-mutated, vorasidenib is now approved, which is a patient population in our brain tumor patient that are our patient that we know have what we normally were calling in the past low-grade tumor. So, tumor that are normally more slower growing, and thus that the patient will live with for many years, and often have more seizures, and be younger patient that often was still at school, or working, or starting a family. So, this is a big victory, having a drug that is family approved that we know is allowing us to delay the time that those patient will need additional brain surgery, or even delay the time that they will need radiation therapy or chemotherapy that are more toxic.

It also makes that there is excitement, right, in keeping working in other brain tumor because I think that in general, brain cancer has a bad reputation of being a bad cancer where nothing works. And now we can show the world that there is a drug that works, that helps this young patient population, that helps those patients that you know, and also that we need to keep working for our patient, and we can make progress in discovery in all our brain tumor patient. So, this was a big victory and it's very exciting.